Dr. Leventhal's principal clinical research focus as a faculty member has been to investigate skin, hair and nail toxicities from cancer therapies. He has published in high impact journals and presented his work at national and international conferences (American Academy of Dermatology, World Congress of Dermatology). He serves as a Principal Investigator on several clinical trials studying rashes from new types of cancer therapies, and collaborates closely with medical oncologists, surgical oncologists and radiation oncologists as a sub-investigator on many trials at the Yale Cancer Center.
dermatology toxicities; cutaneous immune-related adverse events
Drug Eruptions; Dermatology; Melanoma
Conditions | Study Title |
---|---|
Other Skin | A Phase II Study to Evaluate the Safety and Efficacy of OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients |
Brain and Nervous System | Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas |